Dolutegravir-Associated Hyperglycemia in People Living with Human Immune-Deficiency Virus: A Prospective Cohort Study

Background Diabetes mellitus is being related with developing communicable and non-communicable diseases. Patients on highly active anti-retroviral therapy are at increased risk of developing diabetes mellitus than those who are treatment naïve. Hyperglycemia has been mentioned as the side effect of Some ART regimens. We assessed the incidence of hyperglycemia among patients taking Dolutegravir-based regimen in ACSH. Method A Hospital-based prospective cohort study was conducted. The total sample size was 423. A simple random sampling technique was employed using excel function to select study participants. Four categories of data were collected, namely socio-economic, clinical and immunological, regimen type and outcome variables. Results A total of 421 HIV patients were included in the study. More than one-third (36.1%) of the subjects had an exposure to TDF + 3TC + DTG drug therapy, either as a first therapy or a change to the first line triple therapy. Sixty two (14.7%) had hyperglycemia from the study participants. Our finding showed that taking Dolutegravir-based ART has no effect on the blood sugar level of patients, while adjusting for age, sex, and weight at HAART initiation (AOR = 1.04, 95% CI: 0.55–1.95, p = 0.896) Conclusion Dolutegravir-based ART regimen has no effect on the blood sugar level of patients.